Sales Of Biologics was the largest of Adia Nutrition, Inc.’s 8 reported lines in fiscal 2025, at $443.75K — 63% of $705.20K.
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Sales Of Biologics | — | $443.75K |
| Medical Procedures | — | $245.60K |
| Shipping & Delivery | — | $5.14K |
| Sales Of Prducts & Services | $6.38K | $3.39K |
| Sales Of Supplements | $6.38K | $3.39K |
| Services | — | $2.27K |
| Supplements | — | $1.30K |
| Sales Of Ancillary Products | — | $360 |
| Total | $12.76K | $705.20K |
In fiscal 2025, which ended December 31, 2025, the 8 revenue lines Adia Nutrition, Inc. reported in this breakdown added up to $705.20K. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $12.76K reported that year. Sales Of Biologics was the largest revenue line, at $443.75K or 62.9% of the total, followed by Medical Procedures ($245.60K, 34.8%) and Shipping & Delivery ($5.14K, 0.7%). Together, the two largest revenue lines made up 97.8% of this total.
Sales Of Biologics (fiscal 2025), Medical Procedures (fiscal 2025), Shipping & Delivery (fiscal 2025) and Services (fiscal 2025) were first reported as separate revenue lines during this period. This breakdown covers every fiscal year from 2024 to 2025, as reported in Adia Nutrition, Inc.'s annual filings.
Adia Labs was the largest of Adia Nutrition, Inc.’s 4 reported lines in fiscal 2025, at $448.89K — 64% of $700.51K.
| Segment | FY 2024 | FY 2025 |
|---|---|---|
| Adia Labs | — | $448.89K |
| Adia Med | — | $245.96K |
| Biolete | $6.38K | $3.39K |
| Corporate | — | $2.27K |
| Total | $6.38K | $700.51K |
In fiscal 2025, which ended December 31, 2025, the 4 segments Adia Nutrition, Inc. reported in this breakdown added up to $700.51K. The segments reported changed from fiscal 2024, so the total is not directly comparable with the $6.38K reported that year. Adia Labs was the largest segment, at $448.89K or 64.1% of the total, followed by Adia Med ($245.96K, 35.1%) and Biolete ($3.39K, 0.5%). Together, the two largest segments made up 99.2% of this total.
Adia Labs (fiscal 2025), Adia Med (fiscal 2025) and Corporate (fiscal 2025) were first reported as separate segments during this period. This breakdown covers every fiscal year from 2024 to 2025, as reported in Adia Nutrition, Inc.'s annual filings.
Adia Nutrition, Inc. (ADIA) breaks its revenue down by revenue line and segment. In fiscal 2025, its largest revenue line was Sales Of Biologics, with $443.75K or 62.9% of the total, followed by Medical Procedures at $245.60K (34.8%).
Sales Of Biologics was Adia Nutrition, Inc.'s largest revenue line in fiscal 2025, with $443.75K in revenue, 62.9% of the $705.20K reported across its 8 revenue lines.
Adia Labs was Adia Nutrition, Inc.'s largest segment in fiscal 2025, with $448.89K in revenue, 64.1% of the $700.51K reported across its 4 segments.
Every figure is taken from Adia Nutrition, Inc.'s annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2024 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.